公开(公告)号：EP1454909B1

公开(公告)日：2008-08-20

申请号：EP03290569

申请日：2003-03-07

申请人： SANOFI AVENTIS ,  MITSUBISHI PHARMA CORP

发明人： GEORGE PASCAL ,  LOCHEAD ALISTAIR W ,  SAADY MOURAD ,  SLOWINSKI FRANK ,  YAICHE PHILIPPE

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P25/28 ,  C07D487/10

CPC分类号： C07D487/10

公开(公告)号：EP1386606A4

公开(公告)日：2007-12-12

申请号：EP02724736

申请日：2002-05-09

申请人： MITSUBISHI PHARMA CORP

发明人： YOSHIDA HIROSHI ,  MATSUO NAOKI ,  CHIBA MASATOSHI

IPC分类号： A61K31/4152 ,  A61K9/08 ,  A61K47/10 ,  A61K47/18 ,  A61P9/00 ,  A61P9/10 ,  C07D231/20

CPC分类号： C07D231/20 ,  A61K9/0019 ,  A61K31/4152 ,  A61K47/10 ,  A61K47/186

摘要： An injection which contains as the active ingredient a pyrazolone derivative which typically is edaravon, a physiologically acceptable salt thereof, or a hydrate or solvate of either in an amount of 3 to 60 mg/mL. It is excellent in long-term stability, product storage, and suitability for use.

公开(公告)号：EP1760158A4

公开(公告)日：2007-09-12

申请号：EP05741434

申请日：2005-05-18

申请人： MITSUBISHI PHARMA CORP

发明人： UMEDA ASAMI ,  NAGAKI SUMIKO

IPC分类号： C12Q1/02 ,  C12N5/08 ,  G01N21/64 ,  G01N21/77 ,  G01N33/50

CPC分类号： G01N33/5008 ,  G01N21/6428 ,  G01N33/5079

摘要： A simple highly accurate method of assaying a drug capable of changing a mitochondrial membrane potential, in which the mitochondrial membrane potential of cultured cells is used as an index. There is provided a method comprising measuring, as a change of fluorescence intensity of fluorescent dye, any change of mitochondrial membrane potential brought about by adding a regulating agent for ion permeation on cell membrane to a cell culture solution in the presence of an analyte and assaying the mitochondrial membrane potential changing capability of the analyte with the use of the measured change of mitochondrial membrane potential as an index.

公开(公告)号：EP1542017A4

公开(公告)日：2007-07-11

申请号：EP03762879

申请日：2003-07-04

申请人： MITSUBISHI PHARMA CORP

发明人： HASHIMOTO KENJI ,  IYO MASAOMI ,  FUKUSHIMA TAKESHI ,  IMAI KAZUHIRO

IPC分类号： G01N30/02 ,  G01N33/68 ,  G01N30/88 ,  G01N33/50

CPC分类号： G01N33/6812 ,  G01N33/6896 ,  G01N2030/027 ,  G01N2800/302

摘要： A method of examining and diagnosing integration dysfunction syndrome characterized by comprising measuring the concentrations of D-serine and L-seine in a biological sample. According to this method, integration dysfunction syndrome can be examined and diagnosed by measuring the concentrations of D-serine and L-seine in a biological sample by using an analytical technique such as high-performance liquid chromatography.

公开(公告)号：EP1295607A4

公开(公告)日：2007-03-28

申请号：EP01941192

申请日：2001-06-22

申请人： MITSUBISHI PHARMA CORP

发明人： FUJII AKIHIRO ,  TANAKA HIROSHI ,  OTSUKI MAKIO ,  KAWAGUCHI TAKAFUMI ,  OSHITA KOUICHI

IPC分类号： A61K45/00 ,  A61K31/27 ,  A61K31/335 ,  A61K31/337 ,  A61K31/415 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/519 ,  A61K31/7048 ,  A61K33/24 ,  A61K45/06 ,  A61P35/00 ,  A61P43/00 ,  C07D213/75 ,  C07D213/79 ,  C07D213/82 ,  C07D213/89

CPC分类号： A61K45/06 ,  A61K31/27 ,  A61K31/335 ,  A61K31/337 ,  A61K31/415 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/444 ,  A61K31/4453 ,  A61K31/4545 ,  A61K31/50 ,  A61K31/501 ,  A61K31/505 ,  A61K31/519 ,  A61K31/7048 ,  A61K33/24 ,  A61K2300/00

摘要： When used together with antitumor agents, compounds having an Rho kinase inhibitory activity such as (R)-(+)-N-(4-pyridyl)-4-(1-aminoethyl)benzamide can potentiate the antitumor effect of the antitumor agents. Thus, these compounds are useful as antitumor effect potentiators. In particular, the combined use of these compounds having an Rho kinase inhibitory activity with antitumor agents makes it possible to reduce the dose of the antitumor agents, thereby presenting a sufficient effect and/or relieving side effects.

公开(公告)号：EP1437137A4

公开(公告)日：2006-05-10

申请号：EP02760833

申请日：2002-09-13

申请人： MITSUBISHI PHARMA CORP

发明人： YAMADA KEIICHI ,  KURITA KATSUMI ,  TANAKA TADASHI ,  TANAKA MASAHIKO ,  EGUCHI JYUNICHI ,  YUKI SATOSHI ,  YOSHII NARIHIKO

IPC分类号： A61K31/415 ,  A61K45/06 ,  A61P9/10 ,  C07D231/20 ,  C07D231/22 ,  C07D231/26 ,  C07D231/28 ,  C07D231/56 ,  A61K31/4545 ,  A61K45/00 ,  A61P7/02

CPC分类号： C07D231/56 ,  A61K31/415 ,  A61K31/4174 ,  A61K31/4545 ,  C07D231/20 ,  C07D231/22 ,  C07D231/26 ,  C07D231/28 ,  A61K2300/00

摘要： It is intended to provide drugs for treating and/or preventing ischemic diseases which are safe and have little side effects. Namely, drugs comprising a combination of an antithrombotic agent and a pyrazolone derivative defined in the description or its pharmaceutically acceptable salt.

公开(公告)号：EP1574521A4

公开(公告)日：2006-04-12

申请号：EP03780938

申请日：2003-12-19

申请人： MITSUBISHI PHARMA CORP

发明人： SASAKI KENJI ,  KATSUMURA YASUHIKO

IPC分类号： C07K1/00 ,  C07K1/06 ,  C07K1/107 ,  C12P21/08 ,  C07K16/00 ,  A61K39/395 ,  C12N15/09

CPC分类号： C07K1/066 ,  C07K1/006 ,  C07K1/1077

摘要： A method of protecting thiol groups of a protein having a free cysteine residue, which comprises adding a compound which has a disulfide bond in the molecule and exerts substantially no influence on the activity of the protein.

公开(公告)号：EP1559725A4

公开(公告)日：2005-12-14

申请号：EP03751332

申请日：2003-10-03

申请人： MITSUBISHI PHARMA CORP

发明人： HIRAKAWA YOUKO ,  NIKI HISAE ,  OIKE SHINSUKE ,  TAGAWA TOSHIAKI ,  HOSOKAWA SAIKO ,  YOSHIYAMA YOSHIKO

IPC分类号： A61K9/127 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/10 ,  A61P35/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/30 ,  A61K51/00 ,  C07K16/28 ,  C12N15/09

CPC分类号： A61K49/0002 ,  A61K9/127 ,  A61K39/39558 ,  A61K47/6913 ,  A61K51/1045 ,  A61K2039/505 ,  C07K14/4748 ,  C07K14/705 ,  C07K16/30 ,  C07K16/3046

摘要： An antigen having a part which is exposed on the surface of cells in the course of the formation of a tumor mass in the cells. A medicinal composition containing a ligand which recognizes the above antigen, and a labeling.

公开(公告)号：EP1411357A4

公开(公告)日：2005-08-24

申请号：EP02751682

申请日：2002-07-25

申请人： MITSUBISHI PHARMA CORP

发明人： NIKI HISAE ,  TAGAWA TOSHIAKI ,  HOSOKAWA SAIKO

IPC分类号： C07K16/30 ,  G01N33/533 ,  G01N33/574 ,  G01N33/577 ,  G01N33/58 ,  G01N33/48

CPC分类号： G01N33/582 ,  C07K16/3015 ,  C07K16/3046 ,  C07K2317/21 ,  C07K2317/54 ,  G01N33/533 ,  G01N33/574 ,  G01N33/577

摘要： Diagnostics which comprise a peptide or a protein capable of recognizing at least a part of a tissue slice and a fluorescent substance characterized by (1) having a fluorescent wavelength not close to the wavelength region of a non−specific autofluorescence of the tissue slice at a definite excitation wavelength, and (2) allowing simultaneous observation of the image of the peptide or the protein and the image of the tissue slice; a diagnostic method and diagnostic kits with the use of the above−described peptide or protein and the fluorescent substance; remedies for diseases which are to be administered after selecting an appropriate drug by using the above method; tissue slices stained with the use of the above−described peptide or protein and the fluorescent substance; and a method of analyzing the expression and/or behaviors of a protein with the use of the above−described fluorescent substance.

公开(公告)号：EP1293564A4

公开(公告)日：2005-08-17

申请号：EP01936890

申请日：2001-06-07

申请人： MITSUBISHI PHARMA CORP

发明人： SHIBUI TATSUROU ,  KITOU MASAHIRO ,  FUKANO YASUFUMI ,  ITAMI SEIMA

IPC分类号： C12N15/12 ,  C12N15/65 ,  C12N15/85 ,  C12N15/09 ,  C12N5/10 ,  C12P21/02 ,  C12Q1/42 ,  C12Q1/66

CPC分类号： C12N15/65 ,  C12N15/85 ,  C12N2800/30 ,  C12N2840/20 ,  C12N2840/203

摘要： An expression vector characterized by containing an expression unit containing a first selection marker gene and another expression unit containing a second selection marker gene which is different from the above-described first selection marker gene; a transformant having this expression vector; a method of screening cells with the high expression of a recombinant protein with the use of this transformant; and the like. Thus, an expression vector which makes it possible to efficiently screen a recombinant capable of highly expressing a target protein (in particular, a strain capable of highly producing cultured animal cells) at a high reproducibility can be provided.